SCHEMBL20914414

SCHEMBL20914414

COc1cccc2oc(-c3c(C)[nH]c4c(-c5ccccn5)c(C(F)(F)F)nn4c3=O)nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ HSD17B10 Q99714 3/20 0.37
▸ TP53 P04637 3/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ CBFB Q13951 1/20 0.37
▸ F2RL3 Q96RI0 4/20 0.35
▸ KMT2A Q03164 3/20 0.33
▸ HTT P42858 3/20 0.33
▸ TDP1 Q9NUW8 2/20 0.33
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ HSP90AA1 P07900 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33
▸ APLNR P35414 4/20 0.33
▸ TNKS O95271 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20819069 0.89 TNKS (0.37) ALDH1A1HSD17B10TP53CYP3A4HPGD
SCHEMBL20914037 0.89 TSHR (0.39) SMN1; SMN2ALDH1A1HSD17B10CYP3A4F2RL3
SCHEMBL20914243 0.87 F2RL3 (0.35) HSD17B10F2RL3HTTMAPTTNKS
SCHEMBL20913903 0.87 HTT (0.36) ALDH1A1HSD17B10TP53CYP3A4F2RL3
SCHEMBL20931264 0.87 TNKS (0.39) HSD17B10F2RL3HTTMAPTTNKS
SCHEMBL20837034 0.87 TNKS (0.39) ALDH1A1HPGDF2RL3KMT2AHTT
SCHEMBL20914062 0.86 TNKS (0.39) HPGDF2RL3KMT2AMAPTNPSR1
SCHEMBL20914116 0.85 KDM4E (0.33) SMN1; SMN2ALDH1A1TP53F2RL3KMT2A
SCHEMBL20913957 0.85 TNKS (0.34) SMN1; SMN2ALDH1A1HSD17B10TP53HPGD
SCHEMBL20914030 0.85 PSEN1 (0.35) ALDH1A1HSD17B10HPGDCYP2C19F2RL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 SMN1; SMN2 1134/4885ALDH1A1 1246/4885HSD17B10 3047/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 SMN1; SMN2 1134/4885ALDH1A1 1246/4885HSD17B10 3047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback